TG4050 has demonstrated its potential to prime an adaptive immune response against tumour ... which is currently enrolling patients in a phase II part. myvac is a viral vector (MVA—Modified Vaccinia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback